Status:
COMPLETED
Study On Liprimar (Atorvastatin) In Patients With Coronary Heart Disease (CHD) And High Risk Of Cardiovascular Complications
Lead Sponsor:
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Conditions:
Cardiovascular Diseases
Coronary Artery Disease
Eligibility:
All Genders
18-80 years
Brief Summary
In which CHD patients with high risk of CV complications are different doses of LIPRIMAR used? For this purpose, data on hyperlipidemia will be elicited over and above the basic nosographic and demogr...
Eligibility Criteria
Inclusion
- Patients, who eligible to sign informed consent;
- Patients with indications to lipid lowing therapy, according to local product document.
- Patients with CHD and high risk of CV complications (Diabetes Mellitus II, Myocardial Infarction, Heart Failure, Arterial Hypertension, ets) will be included into study;
- Patients with LDL levels: \> 3,5 mmol/l
Exclusion
- Individual intolerance of atorvastatin, in accordance to local product document.
Key Trial Info
Start Date :
April 1 2010
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 1 2011
Estimated Enrollment :
687 Patients enrolled
Trial Details
Trial ID
NCT00993915
Start Date
April 1 2010
End Date
December 1 2011
Last Update
February 18 2021
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.